Comparative Pharmacology
Head-to-head clinical analysis: PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE versus TRINALIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE versus TRINALIN.
PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE vs TRINALIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phenylephrine is a selective alpha-1 adrenergic receptor agonist causing vasoconstriction; promethazine is a phenothiazine derivative that blocks histamine H1 receptors and has anticholinergic, antiemetic, and sedative effects.
TRINALIN is a combination of azatadine, a first-generation antihistamine that antagonizes histamine H1 receptors, and pseudoephedrine, a sympathomimetic amine that stimulates alpha-adrenergic receptors, causing vasoconstriction and reducing nasal congestion.
IV: 0.1-0.5 mg phenylephrine and 12.5-25 mg promethazine as a single dose.
One tablet (azatadine 1 mg/pseudoephedrine 120 mg) orally every 12 hours. Not to exceed 2 tablets in 24 hours.
None Documented
None Documented
Phenylephrine: 2-3 hours (terminal). Promethazine: 10-14 hours (terminal in adults; prolonged in elderly and hepatic impairment).
Terminal elimination half-life approximately 20-30 hours; clinical context: allows twice-daily dosing for sustained decongestant effect
Phenylephrine: renal (80% as unchanged drug and sulfate conjugates). Promethazine: renal (70-80% as metabolites and unchanged drug), fecal (20-30%).
Renal: 70-80% as unchanged drug and metabolites; biliary/fecal: 20-30%
Category A/B
Category C
Antihistamine / Antiemetic
Antihistamine/Decongestant